Wiemer EAC - Search Results

1

Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.

Wiemer EAC, Wozniak A, Burger H, Smid M, Floris G, Nzokirantevye A, Sciot R, Sleijfer S, Schöffski P. Wiemer EAC, et al. Eur J Cancer. 2017 Apr;75:33-40. doi: 10.1016/j.ejca.2016.12.018. Epub 2017 Feb 16. Eur J Cancer. 2017. PMID: 28214655 Clinical Trial.

2

RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.

Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klijn JG, Wiemer EA, Stoter G, Nooter K. Burger H, et al. Clin Cancer Res. 2003 Feb;9(2):827-36. Clin Cancer Res. 2003. PMID: 12576456

3

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K. Burger H, et al. Blood. 2004 Nov 1;104(9):2940-2. doi: 10.1182/blood-2004-04-1398. Epub 2004 Jul 13. Blood. 2004. PMID: 15251980 Free article.

4

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.

Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K. Burger H, et al. Cancer Biol Ther. 2005 Jul;4(7):747-52. doi: 10.4161/cbt.4.7.1826. Epub 2005 Jul 9. Cancer Biol Ther. 2005. PMID: 15970668 Free article.

5

Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.

Burger H, den Bakker MA, Kros JM, van Tol H, de Bruin AM, Oosterhuis W, van den Ingh HF, van der Harst E, de Schipper HP, Wiemer EA, Nooter K. Burger H, et al. Cancer Biol Ther. 2005 Nov;4(11):1270-4. doi: 10.4161/cbt.4.11.2253. Epub 2005 Nov 18. Cancer Biol Ther. 2005. PMID: 16294026 Free article.

6

Practical aspects of managing gastrointestinal stromal tumors.

Sleijfer S, Seynaeve C, Wiemer E, Verweij J. Sleijfer S, et al. Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S18-23. doi: 10.3816/ccc.2006.s.003. Clin Colorectal Cancer. 2006. PMID: 17101064 Review.

7

The role of microRNAs in cancer: no small matter.

Wiemer EA. Wiemer EA. Eur J Cancer. 2007 Jul;43(10):1529-44. doi: 10.1016/j.ejca.2007.04.002. Epub 2007 May 24. Eur J Cancer. 2007. PMID: 17531469 Review.

8

Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.

Sleijfer S, Wiemer E, Seynaeve C, Verweij J. Sleijfer S, et al. Oncologist. 2007 Jun;12(6):719-26. doi: 10.1634/theoncologist.12-6-719. Oncologist. 2007. PMID: 17602061 Free article.

9

Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment.

Sleijfer S, Wiemer E, Verweij J. Sleijfer S, et al. Nat Clin Pract Oncol. 2008 Feb;5(2):102-11. doi: 10.1038/ncponc1037. Nat Clin Pract Oncol. 2008. PMID: 18235442 Review.

10

Dose selection in phase I studies: why we should always go for the top.

Sleijfer S, Wiemer E. Sleijfer S, et al. J Clin Oncol. 2008 Apr 1;26(10):1576-8. doi: 10.1200/JCO.2007.15.5192. Epub 2008 Mar 10. J Clin Oncol. 2008. PMID: 18332465 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

151 results

Search Page

Filters